Commercial developmentNot yet assessedWe only state a stage once a source supports it. Having a product on sale does not show it works or makes money.
Investment accessNo accessible investment route verifiedPast private offerings were limited to eligible investors. They are records of earlier sales, not open offers. · checked Oct 28, 2026

Evidence is labelled on each development below (company-reported, regulatory filing or government record), not on the company as a whole. Coverage is not an offer to invest. Private ownership does not imply available shares. Next scheduled recheck: Nov 27, 2026.

1developments published
—US federal obligations on record
5private-offering notices since 2019
Apr 24, 2026latest development

Timeline

  1. Apr 24, 2026 · Private financing (Form D)

    Life Biosciences reports $31 million of equity sold in a private offering

    Regulatory filing

Profile

Legal name
Life Biosciences LLC
Incorporated
DE
Coverage
Offering notices + any filings + federal awards

Mix of developments

Watch Life Biosciences

Anything new from Life Biosciences lands in your digest, with the source beside it. Following is about information, never an investment action. Up to 10 companies or frontiers on Pro, $49/month.

Follow this companyPreview a sample digest

Private offerings reported to the SEC (Form D)

A Form D is a notice a company files after selling securities without a public registration. Amount sold is cumulative for that offering as reported by the company; an amendment (D/A) updates an earlier notice, so rows are not added together. None of these is a valuation or an open offer.

FiledFormAmount soldOffering sizeFirst saleInvestorsExemptionRecord
Apr 24, 2026D$31.0 million$31.0 millionNov 25, 20258Rule 506(b)SEC ↗
Jun 11, 2021D/A$74.8 million$100.0 millionMay 29, 202035Rule 506(b)SEC ↗
Sep 23, 2020D$0.00No fixed totalSep 8, 20206Rule 506(b)SEC ↗
Jun 12, 2020D$18.2 million$100.0 millionMay 29, 202010Rule 506(b)SEC ↗
Jan 2, 2019D/A$48.6 million$50.9 millionAug 16, 201845Rule 506(c)SEC ↗